JP2019207242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019207242A5 JP2019207242A5 JP2019126244A JP2019126244A JP2019207242A5 JP 2019207242 A5 JP2019207242 A5 JP 2019207242A5 JP 2019126244 A JP2019126244 A JP 2019126244A JP 2019126244 A JP2019126244 A JP 2019126244A JP 2019207242 A5 JP2019207242 A5 JP 2019207242A5
- Authority
- JP
- Japan
- Prior art keywords
- interleukin
- blood sample
- whole blood
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 22
- 210000000822 natural killer cell Anatomy 0.000 claims 21
- 102000004127 Cytokines Human genes 0.000 claims 12
- 108090000695 Cytokines Proteins 0.000 claims 12
- 210000004369 blood Anatomy 0.000 claims 11
- 239000008280 blood Substances 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000003810 Interleukin-18 Human genes 0.000 claims 6
- 108090000171 Interleukin-18 Proteins 0.000 claims 6
- 230000000087 stabilizing effect Effects 0.000 claims 6
- 230000000638 stimulation Effects 0.000 claims 6
- 102000003812 Interleukin-15 Human genes 0.000 claims 5
- 108090000172 Interleukin-15 Proteins 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 108010074328 Interferon-gamma Proteins 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 102000013462 Interleukin-12 Human genes 0.000 claims 3
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940117681 interleukin-12 Drugs 0.000 claims 3
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 2
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 102000004963 gamma-Synuclein Human genes 0.000 claims 2
- 108090001121 gamma-Synuclein Proteins 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims 1
- 230000006051 NK cell activation Effects 0.000 claims 1
- 102000019355 Synuclein Human genes 0.000 claims 1
- 108050006783 Synuclein Proteins 0.000 claims 1
- 102000003802 alpha-Synuclein Human genes 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 102000003799 beta-Synuclein Human genes 0.000 claims 1
- 108090000182 beta-Synuclein Proteins 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021197948A JP2022043119A (ja) | 2011-02-14 | 2021-12-06 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110012983A KR20120093002A (ko) | 2011-02-14 | 2011-02-14 | Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 |
| KR10-2011-0012983 | 2011-02-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017069908A Division JP6798922B2 (ja) | 2011-02-14 | 2017-03-31 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197948A Division JP2022043119A (ja) | 2011-02-14 | 2021-12-06 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019207242A JP2019207242A (ja) | 2019-12-05 |
| JP2019207242A5 true JP2019207242A5 (enExample) | 2020-02-06 |
Family
ID=46672988
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553044A Active JP6629497B2 (ja) | 2011-02-14 | 2012-02-10 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2017069908A Active JP6798922B2 (ja) | 2011-02-14 | 2017-03-31 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2019126244A Pending JP2019207242A (ja) | 2011-02-14 | 2019-07-05 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2021197948A Withdrawn JP2022043119A (ja) | 2011-02-14 | 2021-12-06 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2023076634A Active JP7660605B2 (ja) | 2011-02-14 | 2023-05-08 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553044A Active JP6629497B2 (ja) | 2011-02-14 | 2012-02-10 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2017069908A Active JP6798922B2 (ja) | 2011-02-14 | 2017-03-31 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197948A Withdrawn JP2022043119A (ja) | 2011-02-14 | 2021-12-06 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2023076634A Active JP7660605B2 (ja) | 2011-02-14 | 2023-05-08 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11442069B2 (enExample) |
| EP (1) | EP2676139B1 (enExample) |
| JP (5) | JP6629497B2 (enExample) |
| KR (3) | KR20120093002A (enExample) |
| CN (1) | CN103370622B (enExample) |
| AU (2) | AU2012219184A1 (enExample) |
| BR (1) | BR112013020454B1 (enExample) |
| CA (1) | CA2826053C (enExample) |
| CL (1) | CL2013002361A1 (enExample) |
| DK (1) | DK2676139T3 (enExample) |
| EA (1) | EA038959B1 (enExample) |
| ES (1) | ES2797549T3 (enExample) |
| IL (1) | IL227952B (enExample) |
| MX (1) | MX361731B (enExample) |
| MY (1) | MY175351A (enExample) |
| RU (1) | RU2635194C2 (enExample) |
| SG (1) | SG192247A1 (enExample) |
| TW (2) | TWI668445B (enExample) |
| UA (1) | UA120697C2 (enExample) |
| WO (1) | WO2012110878A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120093002A (ko) | 2011-02-14 | 2012-08-22 | (주)에이티젠 | Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 |
| WO2015069187A1 (en) | 2013-11-05 | 2015-05-14 | Agency For Science, Technology And Research | Bladder Carcinoma Biomarkers |
| JP6073417B2 (ja) * | 2015-06-26 | 2017-02-01 | チャ バイオテック カンパニー リミテッド | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| WO2017204446A2 (ko) * | 2016-05-24 | 2017-11-30 | 울산대학교 산학협력단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| CN106222140A (zh) * | 2016-08-04 | 2016-12-14 | 英普乐孚生物技术(上海)有限公司 | 一种nk细胞无血清培养基及其配制方法 |
| CN107686828A (zh) * | 2016-08-04 | 2018-02-13 | 英普乐孚生物技术(上海)有限公司 | 一种nk细胞无血清培养基 |
| CN106085958A (zh) * | 2016-08-04 | 2016-11-09 | 英普乐孚生物技术(上海)有限公司 | 一种nk细胞的制备方法 |
| BR112019016374A2 (pt) | 2017-02-17 | 2020-04-07 | Bristol-Myers Squibb Company | anticorpos para alfa-sinucleína e usos dos mesmos |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR102090698B1 (ko) * | 2017-08-24 | 2020-04-23 | 연세대학교 산학협력단 | 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법 |
| JP7268039B2 (ja) | 2018-02-01 | 2023-05-02 | エヌケーマックス カンパニー リミテッド | がん治療のためのナチュラルキラー細胞および組成物の製造方法 |
| EP3924368A4 (en) * | 2019-02-14 | 2022-12-14 | Research Institute at Nationwide Children's Hospital | USE OF A STIMULATING AGENT TO ANALYZE THE POTENCY OF IMMUNE CELLS |
| WO2021041399A1 (en) * | 2019-08-29 | 2021-03-04 | Board Of Regents, The University Of Texas System | Cell cryopreservation medium |
| CN112552391B (zh) * | 2019-09-25 | 2024-08-23 | 北京志道生物科技有限公司 | 一种重组白介素-15类似物 |
| CN114929249A (zh) * | 2019-11-29 | 2022-08-19 | Nkmax有限公司 | 产生自然杀伤细胞及其组合物的方法 |
| WO2022024693A1 (ja) * | 2020-07-29 | 2022-02-03 | 国立大学法人東北大学 | シヌクレイノパチーを予防又は治療するために使用されるペプチド |
| CN113533729B (zh) * | 2021-06-15 | 2024-09-06 | 北京大学人民医院 | 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用 |
| EP4448554A1 (en) * | 2021-12-17 | 2024-10-23 | University of Kent | Sequences and methods for production of recombinant biological molecules in vesicles |
| KR20230156518A (ko) | 2022-05-06 | 2023-11-14 | (주)다이오진 | 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트 |
| CN115247149B (zh) * | 2022-08-22 | 2023-06-16 | 华域生物科技(天津)有限公司 | 适用于nk细胞的培养基组合物及培养方法 |
| CN115855779A (zh) * | 2023-01-18 | 2023-03-28 | 山东康华生物医疗科技股份有限公司 | 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2635088A (en) * | 1987-12-04 | 1989-06-08 | Du Pont Merck Pharmaceutical Company, The | Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension |
| HUT74425A (en) * | 1993-08-09 | 1996-12-30 | Baral | A method for sensitization of cancer for killer cell mediated lysis |
| WO1996024369A1 (en) * | 1995-02-06 | 1996-08-15 | Genetics Institute, Inc. | Formulations for il-12 |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7781210B2 (en) | 2001-08-13 | 2010-08-24 | Junjiro Tsuchiyama | Epstein-Barr virus-negative NK cell line |
| EP1451217A4 (en) * | 2001-11-20 | 2005-10-12 | Atgen Co Ltd | NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES |
| AU2003220557A1 (en) * | 2002-03-26 | 2003-10-13 | Centocor, Inc. | Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses |
| JP2004305095A (ja) | 2003-04-07 | 2004-11-04 | Limuloid Science Kk | 細胞活性化検出方法 |
| CN1297567C (zh) * | 2003-06-13 | 2007-01-31 | 马菁 | 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用 |
| ATE500267T1 (de) * | 2003-07-21 | 2011-03-15 | Transgene Sa | Multifunktionelle cytokine |
| WO2005013950A2 (en) | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| CA2542886A1 (en) | 2003-11-05 | 2005-05-19 | Neelima M. Bhat | Enhanced b cell cytotoxicity of cdim binding antibody |
| KR100565764B1 (ko) * | 2005-05-02 | 2006-03-28 | (주)에이티젠 | 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질 |
| WO2005108423A1 (en) | 2004-05-11 | 2005-11-17 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| JP4653465B2 (ja) | 2004-10-25 | 2011-03-16 | 泰信 小林 | ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物 |
| EP1901766A2 (en) * | 2005-04-08 | 2008-03-26 | Morningside Venture Investments Limited | Use of fril proteins for reducing the production of pro-inflammatory cytokines |
| WO2008013975A2 (en) * | 2006-07-28 | 2008-01-31 | The Research Foundation Of State University Of New York | Methods and kits for measurement of lymphocyte function |
| WO2008070647A1 (en) * | 2006-12-07 | 2008-06-12 | Wyeth | Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample |
| CN101578113B (zh) | 2007-01-11 | 2015-04-22 | 诺和诺德公司 | 抗-kir抗体、制剂及其应用 |
| EP2048237A1 (en) * | 2007-10-05 | 2009-04-15 | Avir Green Hills Biotechnology Research Development Trade Ag | Replication deficient Influenza virus for the expression of heterologous sequences |
| KR20120093002A (ko) | 2011-02-14 | 2012-08-22 | (주)에이티젠 | Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 |
-
2011
- 2011-02-14 KR KR1020110012983A patent/KR20120093002A/ko active Pending
-
2012
- 2012-02-10 RU RU2013141487A patent/RU2635194C2/ru active
- 2012-02-10 AU AU2012219184A patent/AU2012219184A1/en not_active Abandoned
- 2012-02-10 CN CN201280008685.3A patent/CN103370622B/zh active Active
- 2012-02-10 CA CA2826053A patent/CA2826053C/en active Active
- 2012-02-10 KR KR1020137006311A patent/KR101341538B1/ko active Active
- 2012-02-10 EA EA201391187A patent/EA038959B1/ru unknown
- 2012-02-10 US US13/985,301 patent/US11442069B2/en active Active
- 2012-02-10 JP JP2013553044A patent/JP6629497B2/ja active Active
- 2012-02-10 MY MYPI2013002917A patent/MY175351A/en unknown
- 2012-02-10 DK DK12747246.2T patent/DK2676139T3/da active
- 2012-02-10 KR KR1020137031527A patent/KR101438573B1/ko active Active
- 2012-02-10 BR BR112013020454-0A patent/BR112013020454B1/pt not_active IP Right Cessation
- 2012-02-10 EP EP12747246.2A patent/EP2676139B1/en active Active
- 2012-02-10 MX MX2013009380A patent/MX361731B/es active IP Right Grant
- 2012-02-10 WO PCT/IB2012/000259 patent/WO2012110878A2/en not_active Ceased
- 2012-02-10 UA UAA201310947A patent/UA120697C2/uk unknown
- 2012-02-10 ES ES12747246T patent/ES2797549T3/es active Active
- 2012-02-10 SG SG2013058375A patent/SG192247A1/en unknown
- 2012-02-14 TW TW101104742A patent/TWI668445B/zh active
- 2012-02-14 TW TW106103526A patent/TWI681191B/zh not_active IP Right Cessation
-
2013
- 2013-08-14 IL IL227952A patent/IL227952B/en active IP Right Grant
- 2013-08-14 CL CL2013002361A patent/CL2013002361A1/es unknown
-
2017
- 2017-03-31 JP JP2017069908A patent/JP6798922B2/ja active Active
- 2017-04-20 AU AU2017202628A patent/AU2017202628B2/en not_active Ceased
-
2019
- 2019-07-05 JP JP2019126244A patent/JP2019207242A/ja active Pending
-
2021
- 2021-12-06 JP JP2021197948A patent/JP2022043119A/ja not_active Withdrawn
-
2022
- 2022-03-10 US US17/691,391 patent/US12379384B2/en active Active
-
2023
- 2023-05-08 JP JP2023076634A patent/JP7660605B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019207242A5 (enExample) | ||
| JP2022043119A5 (enExample) | ||
| JP7660605B2 (ja) | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット | |
| Chen et al. | Different expression patterns of plasma Th1‐, Th2‐, Th17‐and Th22‐related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria | |
| Witkowska | On the role of sIL‐2R measurements in rheumatoid arthritis and cancers | |
| Whitehead et al. | The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity | |
| Palmer et al. | The innate immune protein S100A9 protects from T-helper cell type 2–mediated allergic airway inflammation | |
| Hidvégi et al. | Correlation between T-cell and mast cell activity in patients with chronic urticaria | |
| Iellem et al. | Inhibition by IL‐12 and IFN‐α of I‐309 and macrophage‐derived chemokine production upon TCR triggering of human Th1 cells | |
| Matsuda et al. | Cytokine mRNA expression profiles in rats infected with the intestinal nematode Nippostrongylus brasiliensis | |
| Hapnes et al. | Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups | |
| EP0710839B1 (en) | Method of measuring interferon activity | |
| WO2017214609A1 (en) | Uses of il-41 | |
| Naftali et al. | Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation | |
| Pennanen et al. | Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion | |
| Wakatabi et al. | The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid | |
| Krakauer | A sensitive, specific immunobioassay for quantitation of human interleukin 6 | |
| Al-bassam et al. | Biomarker significance of interleukin-18 in juvenile idiopathic arthritis | |
| HASHIMOTO et al. | The Relationship Between Serum levels of Interleukin-6 and Thyroid Hormone During the Follow-up Study in Children with Nonthyroidal Illness Marked Inverse Correlation in Kawasaki and Infectious Disease | |
| Marzinotto et al. | Autoantibody binding in liquid phase to IL-2 in human sera is not type 1 diabetes specific | |
| Valencia et al. | Overview of the cytokine assay multiverse: Systems and applications | |
| Adhikari et al. | Validation of Metabolic and Immunologic Biomarkers TNF-a, IGF, IL-6, CRP and Hair Cortisol in the Common Marmoset | |
| Schaniel et al. | A novel CC chemokine ABCD-1, produced by dendritic cells and activated B cells, exclusively attracts activated T lymphocytes | |
| Krakauer et al. | A method for correcting for the variability of inhibitory effects of soluble human interleukin 1 receptor II measured by different ELISAS | |
| Vivo | Preferential Role for NF |